<DOC>
	<DOCNO>NCT00449072</DOCNO>
	<brief_summary>The primary objective study characterize difference prepubescent growth velocity child 3 9 year age perennial allergic rhinitis ( PAR ) treat triamcinolone acetonide ( TAA ) nasal spray ( NASACORT® AQ 110 μg treatment group ) placebo ( NASACORT® AQ placebo group ) 12-months . The secondary objective compare follow prepubertal participant treat TAA nasal spray versus placebo : - 24-hour urinary free cortisol level cortisol/creatinine ratio ( measure Hypothalamic-Pituitary Adrenal [ HPA ] axis function ) - rate treatment-emergent-adverse-events ( TEAE ) - global efficacy rat investigator participant separately - rate use rescue medication study</brief_summary>
	<brief_title>Study Triamcinolone Acetonide Growth Velocity Children , Ages 3 9 , With Perennial Allergic Rhinitis ( PAR )</brief_title>
	<detailed_description>The study consist : - 4- 6-month screening/baseline period - 12-month ( Day 360+/-5 day ) double-blind treatment period start Day 1 - 2-month follow-up period ( Day 420+/-5 day )</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>Participants meet follow eligibility criterion enrol . Inclusion criterion : 1 . Male participant [ 3 year &lt; = 9 year + 0 day old ] Visit 1 old [ 9 year + 120 day ] Visit 3 ; , female participant [ 3 year &lt; = 8 year + 0 day old ] Visit 1 old [ 8 year + 120 day ] Visit 3 : sexually prepubertal ( ie , Stage 1 Tanner Classification sexual maturity ) Visit 1 Visit 3 . A 5day extension age upper bound permit certain circumstance enable schedule Visits 1 3 2 . At least one year history PAR assess document investigator ( without seasonal allergic rhinitis [ SAR ] ) 3 . Positive skin test ( prick intradermal ) perennial allergen present participant 's environment . A skin test consider positive wheal produce allergen equal great cause positive control ( histamine ) least 3 mm ( prick test ) 7 mm ( intradermal test ) great wheal negative control ( saline ) . If skin test could perform , radioallergosorbent test ( RAST ) would use alternative . Documented historical skin test RAST perform past year acceptable 4 . Height within 3rd 97th percentile screen ( Visit 1 ) , Visit 2 , randomization ( Visit 3 ) 5 . Symptomatic ( daily AM instantaneous total nasal symptom score &gt; = 4 12 ) 4 last 7 consecutive day immediately prior include morning Visit 3 . Symptom rating complete help parent/guardian/caregiver 6 . Written inform consent ability parent legal guardian participant give write informed consent study related procedure . Participants 7 year age old must provide signed assent form 7 . Participants toilettrained Exclusion criterion : 1 . Gross nasal anatomical deformity include large polyposis mark deviated septum 2 . History current cataract glaucoma 3 . History hypersensitivity corticosteroid excipient investigational product 4 . Participant investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol 5 . Height , weight , body mass index ( BMI ) forage 3rd 97th percentile Visits 1 , 2 , 3 6 . Treatment systemic corticosteroid ( oral , intravenous , intramuscular , intraarticular ) within 3 month prior Visit 1 7 . Treatment systemic corticosteroid &gt; 2 course receive 1 year Visit 1 exclusionary . Up 2 course systemic corticosteroid course exceed 14 day 1 year Visit 1 allow . 8 . Treatment inhale , intranasal , high potency topical corticosteroid exposure within 6 week prior Visit 1 . Mild asthma wellcontrolled without use inhaled corticosteroid within 6 week screen ( Visit 1 ) . 9 . Immunotherapy , except stable ( &gt; =1 month ) maintenance schedule Visit 1 . 10 . Treatment substance Visit 1 might affect growth velocity and/or linear growth , , limited methylphenidate hydrochloride , thyroid hormone , growth hormone , anabolic steroid , calcitonin , estrogens , progestin , bisphosphonates , anticonvulsant , phosphatebinding antacid 11 . Treatment investigational product device 30 day Visit 1 time throughout duration trial ( Visit 1 Visit 11 ) . 12 . Bone age assess Xray leave hand wrist outside +/ 1.5 year participant chronological age Visit 2 . Right hand wrist radiographed event bone injury leave hand wrist . 13 . Unresolved upper respiratory tract infection , sinus infection nasal candidiasis ( i.e. , symptomatic treatment ) within last 2 week Visit 3 . 14 . Participants parent/guardian/caregiver unable demonstrate correct administration investigational product Visit 1 . 15 . Concomitant disease PAR could interfere study procedure outcomes determine investigator . 16 . History hospitalization due asthma within 1 year screening ( Visit 1 ) . 17 . Abnormal 24hour urinary free cortisol level assess screening ( Visit 2 ) . The information intend contain consideration relevant potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>